Published in Nat Commun on January 01, 2011
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
Matricellular protein SPARCL1 regulates tumor microenvironment-dependent endothelial cell heterogeneity in colorectal carcinoma. J Clin Invest (2016) 1.43
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol (2014) 1.14
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2013) 1.03
Malignancies in systemic lupus erythematosus. Autoimmun Rev (2009) 1.02
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood (2012) 1.02
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol (2012) 0.99
Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol Med (2013) 0.99
Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res (2012) 0.94
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol (2012) 0.91
Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice. PLoS One (2012) 0.85
Faster cognitive decline in elders without dementia and decreased risk of cancer mortality: NEDICES Study. Neurology (2014) 0.85
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Molecular profiling of tumor-specific TH1 cells activated in vivo. Oncoimmunology (2013) 0.84
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Specific Dioscorea Phytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines. Evid Based Complement Alternat Med (2013) 0.84
IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun (2015) 0.84
Contributions of neutrophils to the adaptive immune response in autoimmune disease. World J Transl Med (2015) 0.83
Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization enhancing the anti-tumor efficacy of doxorubicin nanoliposomes. PLoS One (2014) 0.81
Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol (2014) 0.79
Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer. Curr Oncol (2013) 0.79
The aging immune system and its relationship with cancer. Aging health (2011) 0.79
Expression of a mutant prohibitin from the aP2 gene promoter leads to obesity-linked tumor development in insulin resistance-dependent manner. Oncogene (2016) 0.78
IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med (2016) 0.78
Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. Oncotarget (2015) 0.77
A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. Cancer Epidemiol Biomarkers Prev (2014) 0.76
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Oncotarget (2016) 0.76
Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization. J Immunol (2012) 0.76
SMYD proteins in immunity: dawning of a new era. AIMS Biophys (2016) 0.76
SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS One (2012) 0.76
Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss. Sci Rep (2016) 0.76
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. Oncoimmunology (2015) 0.76
Infections and cancer: the "fifty shades of immunity" hypothesis. BMC Cancer (2017) 0.75
Overview of cancer vaccines: considerations for development. Hum Vaccin Immunother (2012) 0.75
Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med (2016) 0.75
Cancer: A disease at the crossroads of trade-offs. Evol Appl (2016) 0.75
Immunogenicity is preferentially induced in sparse dendritic cell cultures. Sci Rep (2017) 0.75
Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen. Oncoimmunology (2014) 0.75
Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma. World J Gastrointest Pharmacol Ther (2017) 0.75
CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med (2016) 0.75
Metastatic melanoma cells evade immune detection by silencing STAT1. Int J Mol Sci (2015) 0.75
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma. Leukemia (2015) 0.75
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer J (2016) 0.75
Interactions between immune challenges and cancer cells proliferation: timing does matter! Evol Med Public Health (2016) 0.75
Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology (2017) 0.75
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia (2017) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Cancer-related inflammation. Nature (2008) 34.21
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science (1993) 14.91
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Basement membrane complexes with biological activity. Biochemistry (1986) 6.79
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature (1986) 4.06
CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature (2009) 4.03
IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A (2003) 3.80
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
The beige mutation in the mouse selectively impairs natural killer cell function. Nature (1979) 3.15
CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity (2000) 3.07
IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A (2009) 3.07
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med (1995) 2.99
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med (2003) 2.91
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med (1995) 2.68
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J Immunol (1983) 2.61
Inflammation and prognosis in colorectal cancer. Eur J Cancer (2005) 2.47
Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 2.45
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med (1996) 2.14
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2.12
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01
MHC class II-restricted presentation of intracellular antigen. Cell (1991) 2.01
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol (2006) 1.69
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood (1997) 1.63
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A (1996) 1.52
Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine (1999) 1.50
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol (1986) 1.39
Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res (1994) 1.28
Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med (2003) 1.26
Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood (1995) 1.20
Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology (2006) 1.19
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A (1994) 1.17
Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol (2005) 1.17
Potentiation of antitumor effect of virus-induced interferon by mouse immune interferon preparations. J Natl Cancer Inst (1980) 1.14
Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol (1995) 1.08
Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst (1988) 1.04
Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res (2009) 1.03
Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology (2005) 1.00
Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol (2008) 0.84
Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma. Oncol Rep (2006) 0.83
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood (1994) 0.82
Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer (2002) 0.81
iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinformatics (2008) 5.77
PSICQUIC and PSISCORE: accessing and scoring molecular interactions. Nat Methods (2011) 5.01
Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A (2003) 3.98
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J (2006) 3.07
Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol (2003) 2.72
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
iRefWeb: interactive analysis of consolidated protein interaction data and their supporting evidence. Database (Oxford) (2010) 2.47
Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol (2008) 1.76
Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood (2004) 1.61
A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations. J Exp Med (2005) 1.54
Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments. Blood (2004) 1.50
[A pregnant woman with abdominal pain and fever]. Tidsskr Nor Laegeforen (2007) 1.49
Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. J Immunol (2011) 1.39
Literature curation of protein interactions: measuring agreement across major public databases. Database (Oxford) (2010) 1.33
The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies. J Leukoc Biol (2009) 1.25
Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol (2010) 1.21
Characterization of a novel chemokine-containing storage granule in endothelial cells: evidence for preferential exocytosis mediated by protein kinase A and diacylglycerol. J Immunol (2005) 1.20
Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol (2003) 1.13
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol (2008) 1.06
Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol (2005) 1.05
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med (2007) 1.05
Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res (2009) 1.03
Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep (2013) 1.02
Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules. Blood (2005) 1.01
Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol (2007) 1.01
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol (2012) 1.00
iRefR: an R package to manipulate the iRefIndex consolidated protein interaction database. BMC Bioinformatics (2011) 0.99
Interaction databases on the same page. Nat Biotechnol (2011) 0.98
Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS One (2012) 0.96
Vascular morphogenesis and differentiation after adoptive transfer of human endothelial cells to immunodeficient mice. Am J Pathol (2002) 0.95
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood (2007) 0.94
The alarmin IL-33 is a notch target in quiescent endothelial cells. Am J Pathol (2012) 0.94
MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol (2004) 0.93
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood (2003) 0.93
Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther (2004) 0.93
A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol (2002) 0.93
Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus. Eur J Immunol (2014) 0.93
TLR3-responsive, XCR1+, CD141(BDCA-3)+/CD8α+-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques. J Immunol (2014) 0.91
DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther (2006) 0.91
Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol (2012) 0.91
Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol (2004) 0.90
Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J (2005) 0.89
Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood (2004) 0.89
Liprin (beta)1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity. Blood (2009) 0.89
Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer (2011) 0.88
Identification of a novel protein promoting the colonization and survival of Finegoldia magna, a bacterial commensal and opportunistic pathogen. Mol Microbiol (2008) 0.87
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells. Eur J Immunol (2014) 0.87
Molecular requirements for sorting of the chemokine interleukin-8/CXCL8 to endothelial Weibel-Palade bodies. J Biol Chem (2009) 0.86
The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol (2010) 0.86
Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease. J Immunol (2005) 0.86
Expanding the versatility of phage display II: improved affinity selection of folded domains on protein VII and IX of the filamentous phage. PLoS One (2011) 0.86
Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. Immunol Lett (2013) 0.86
DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J Immunol (2013) 0.85
Endostatin suppresses IGF-II-mediated signaling and invasion of human extravillous trophoblasts. Endocrinology (2011) 0.85
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Cytokine secretion depends on Galalpha(1,3)Gal expression in a pig-to-human whole blood model. J Immunol (2008) 0.84
iRefScape. A Cytoscape plug-in for visualization and data mining of protein interaction data from iRefIndex. BMC Bioinformatics (2011) 0.84
Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems. Am J Pathol (2009) 0.84
Molecular profiling of tumor-specific TH1 cells activated in vivo. Oncoimmunology (2013) 0.84
Family-with-sequence-similarity-46, member A (Fam46a) gene is expressed in developing tooth buds. Arch Oral Biol (2009) 0.83
Navigating the global protein-protein interaction landscape using iRefWeb. Methods Mol Biol (2014) 0.83
Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood (2012) 0.83
The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. PLoS One (2013) 0.82
The HUVEC/Matrigel assay: an in vivo assay of human angiogenesis suitable for drug validation. Methods Mol Biol (2007) 0.82
Effects of protein interaction data integration, representation and reliability on the use of network properties for drug target prediction. BMC Bioinformatics (2012) 0.82
Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J Immunol (2002) 0.82
Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines. Vaccine (2010) 0.82
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest (2015) 0.82
Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. Eur J Haematol (2011) 0.82
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Sci Rep (2013) 0.81
Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates. Vaccine (2007) 0.81
Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA). Cell Signal (2008) 0.81
The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br J Nutr (2012) 0.81
CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother (2004) 0.81
Generation and characterization of an immortalized human mesenchymal stromal cell line. Stem Cells Dev (2014) 0.80
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PLoS One (2012) 0.79
Proteome analysis of microtubule-associated proteins and their interacting partners from mammalian brain. Amino Acids (2010) 0.79
CD38 is a marker of human lacteals. Virchows Arch (2002) 0.79
Human serum-induced porcine endothelial cell E-selectin expression is associated with IgG3 and IgM anti-Gal antibodies. Xenotransplantation (2002) 0.79
Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica (2006) 0.79
Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level. Mol Immunol (2007) 0.79
Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA. BMC Biotechnol (2010) 0.78
Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells. PLoS One (2012) 0.78
Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunol Immunother (2004) 0.78
Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. Eur J Immunol (2005) 0.78
A VH4-34+ myeloma protein with weak autoreactivity. Haematologica (2007) 0.78